SPONSOR
Shanghai Kechow Pharma, Inc.
Total Trials
2
Recruiting
2
Phases
Phase 3
Shanghai Kechow Pharma, Inc. is a clinical research sponsor with 2 registered studies on ClinicalTrials.gov, of which 2 are actively recruiting participants. Research covers conditions including Melanoma, Colorectal Cancer Metastatic.
The trial portfolio spans Phase 3 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Shanghai Kechow Pharma, Inc.
How many clinical trials has Shanghai Kechow Pharma, Inc. sponsored?
ClinicalMetric currently tracks 2 clinical trials sponsored by Shanghai Kechow Pharma, Inc., of which 2 are actively recruiting participants. These trials cover conditions including Melanoma, Colorectal Cancer Metastatic. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Shanghai Kechow Pharma, Inc. research focus on?
Shanghai Kechow Pharma, Inc. clinical trials span Melanoma, Colorectal Cancer Metastatic. The research pipeline includes Phase 3 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Shanghai Kechow Pharma, Inc. clinical trial?
To participate in a Shanghai Kechow Pharma, Inc. trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Shanghai Kechow Pharma, Inc. trials with current recruitment status updated daily.
Clinical Trials by Shanghai Kechow Pharma, Inc.
NCT06008106 Phase 3
Recruiting
Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
Melanoma
NCT06008119 Phase 3
Recruiting
Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Colorectal Cancer Metastatic
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology